3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
10
Metastatic Castration-resistant Prostate Cancer
2
Prostatic Neoplasms, Castration-Resistant
1
Metastatic Hormone Naive Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Nivolumab
8
belzutifan
7
pembrolizumab
6
Ipilimumab
5
cabozantinib
3
Surveys and Questionnaires
3
lenvatinib
2
Radiosurgery
2
Paclitaxel
2
Everolimus
2
Carboplatin
2
pazopanib
1
palbociclib
1
liposomal doxorubicin
1
guadecitabine
1
fludarabine phosphate
1
endothelial PAS domain-containing protein 1
1
durvalumab
1
cemiplimab
1
atezolizumab
1
aldesleukin
1
X-Rays
1
Technetium Tc 99m Sestamibi
1
Taxes
1
Sunitinib
1
Spermine Synthase
1
Social Determinants of Health
1
Single Photon Emission Computed Tomography Computed Tomography
1
Radiotherapy
1
Radionuclide Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Kidney Neoplasms
×
Pluvicto
×
Clear all
NCT06964958
2026-02-24
LASER
Dana-Farber Cancer Institute
Phase 2
Active not recruiting
24 enrolled